Last reviewed · How we verify

Active Comparator: GARDASIL ®9 — Competitive Intelligence Brief

Active Comparator: GARDASIL ®9 (Active Comparator: GARDASIL ®9) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant HPV vaccine. Area: Oncology / Immunology / Infectious Disease.

phase 3 Recombinant HPV vaccine Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58 Oncology / Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Active Comparator: GARDASIL ®9 (Active Comparator: GARDASIL ®9) — Shanghai Bovax Biotechnology Co., Ltd.. GARDASIL 9 is a recombinant human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against nine HPV types to prevent infection and associated cancers.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Active Comparator: GARDASIL ®9 TARGET Active Comparator: GARDASIL ®9 Shanghai Bovax Biotechnology Co., Ltd. phase 3 Recombinant HPV vaccine Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58
Gardasil 9 Suspension for Injection Gardasil 9 Suspension for Injection Erasmus Medical Center marketed Recombinant HPV vaccine Human papillomavirus L1 capsid protein (types 6, 11, 16, 18, 31, 33, 45, 52, 58)
Gardasil 9 rescue dose Gardasil 9 rescue dose Boston Medical Center marketed Recombinant HPV vaccine Human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, 58
Gardasil9 Gardasil9 Boston Medical Center marketed Recombinant HPV vaccine HPV L1 capsid protein (types 6, 11, 16, 18, 31, 33, 45, 52, 58)
GSK580299, GSK Biological's HPV vaccine GSK580299, GSK Biological's HPV vaccine GlaxoSmithKline phase 3 Recombinant HPV vaccine Human papillomavirus (HPV) virus-like particles
GSK580299 (CervarixTM) GSK580299 (CervarixTM) GlaxoSmithKline phase 3 Recombinant HPV vaccine Human papillomavirus types 16 and 18 (L1 capsid protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant HPV vaccine class)

  1. Boston Medical Center · 2 drugs in this class
  2. GlaxoSmithKline · 2 drugs in this class
  3. Erasmus Medical Center · 1 drug in this class
  4. Shanghai Bovax Biotechnology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Active Comparator: GARDASIL ®9 — Competitive Intelligence Brief. https://druglandscape.com/ci/active-comparator-gardasil-9. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing